Using biomarkers to identify and treat schizophrenia

In the current online issue of PLoS ONE, researchers at the University of California, San Diego School of Medicine say they have identified a set of laboratory-based biomarkers that can be useful for understanding brain-based abnormalities in schizophrenia. The measurements, known as endophenotypes, could ultimately be a boon to clinicians who sometimes struggle to recognize and treat the complex and confounding mental disorder.

"A major problem in psychiatry is that there are currently no laboratory tests that aid in diagnosis, guide or help predict or outcomes," said Gregory A. Light, PhD, associate professor of psychiatry and the study's first author. "Diagnoses are currently based on a clinician's ability to make inferences about patients' inner experiences."

Diagnosing and treating schizophrenia is a particularly troubling challenge. The disorder, which affects about 1 percent of the U.S. population or roughly 3 million people, is characterized by a breakdown of normal and erratic, sometimes dangerous or harmful, behaviors.

"Schizophrenia is among the most severe and disabling conditions across all categories of medicine," said Light, who also directs the Mental Illness, Research, Education and Clinical Center at the San Diego VA Healthcare System.

The precise cause or causes of schizophrenia are not known, though there is a clear , with the disorder more common in some families.

Clinicians typically diagnose schizophrenia based upon inferences drawn from the patient's inner experiences. That is, their ability to describe what's happening inside their minds.

"But even the best clinicians struggle with diagnostic complexities based on sometimes fuzzy clinical phenomenology," said Light. The clinical challenge is compounded by the fact that "many schizophrenia patients have cognitive and functional impairments," said Light. They may not be able to reasonably explain how or what they think.

Light and colleagues investigated whether a select battery of neurophysiological and neurocognitive biomarkers could provide clinicians with reliable, accurate, long-term indicators of brain dysfunction, even when overt symptoms of the disorder were not apparent. These markers ranged from tests of attention and memory to physiological assessments of basic perceptual processes using scalp sensors to measure brain responses to simple sounds.

The researchers measured the biomarkers in 550 schizophrenia patients, and then re-tested 200 of the patients one year later. They found that most of the markers were significantly abnormal in , were relatively stable between the assessments and were not affected by modest fluctuations in clinical status of the patient.

Light said further research is required, including whether the endophenotypes can differentiate other psychiatric disorders, be used to anticipate patient response to different kinds of drugs or non-pharmacological interventions or even be used to predict which subjects are at high risk of developing a psychotic illness.

"We believe this paper is an important step towards validating laboratory-based for use in future genomic and clinical treatment studies of schizophrenia," Light said.

add to favorites email to friend print save as pdf

Related Stories

Blood test for schizophrenia could be ready this year

Jan 20, 2010

the most serious form of mental illness — could be available this year, according to an article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine. The disorder, with symptoms that can includ ...

Immaturity of the brain may cause schizophrenia

Sep 10, 2008

The underdevelopment of a specific region in the brain may lead to schizophrenia in individuals. According to research published today in BioMed Central's open access journal Molecular Brain, dentate gyrus, which is locate ...

Protein marker for schizophrenia risk

Jul 08, 2008

A protein found in immune cells may be a reliable marker for schizophrenia risk, report researchers in a new proteomics study appearing in the July issue of Molecular and Cellular proteomics.

Recommended for you

No link between psychedelics and mental health problems

8 hours ago

The use of psychedelics, such as LSD and magic mushrooms, does not increase a person's risk of developing mental health problems, according to an analysis of information from more than 135,000 randomly chosen people, including ...

Antibodies to brain proteins may trigger psychosis

8 hours ago

Antibodies defend the body against bacterial, viral, and other invaders. But sometimes the body makes antibodies that attack healthy cells. In these cases, autoimmune disorders develop.

Stigma of mental illness in India linked to poverty

10 hours ago

The stigma surrounding people with severe mental illness in India leads to increased poverty among them, especially women, according to new research led by Jean-Francois Trani, PhD, assistant professor at the Brown School ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.